volume is the keyApart from the noise and the controversy over the re-imbursement rates both commercial and medicare and medicaid, what would be the most important catalyst for the sp is the acquisitions CRH can make so it can develop an economy of scale and offset the rate reductions. This is crucial for the survival and growth of the company and in the long run CRH has the potential to control the market due to its leverage it has with the O'Regan hemmoroid procedure and its contact and training it does of the physicians adopting this procedure. So it's a matter of time that CRH will be a brand name in the market and asert its dominance in the sector.